Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer

Skalleberg, Jakob; Solheim, Olesya; Fosså, Sophie D.; Småstuen, Milada Cvancarova; Osnes, Terje; Gundersen, Per Ole M.; Bunne, Marie

doi:10.1016/j.ygyno.2017.02.006

Cited by 33 publications

(32 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four SCIN questions assessed sensory neuropathy and Raynaud's phenomenon in hands/fingers (abbreviated to "hands") and feet/toes ("feet") using a 4-point Likert scale (0 = "not at all", 1 = "a little", 2 = "quite a bit", 3 = "very much") ( (20) . 26 17 (18) Mental disorders 15 (31) 6 (13) .05 21 (23) Skeleto-muscular problems 2 (4) 4 (10) .32 6 (7) CBCT, cisplastin-based chemotherapy; yr, year.…”

Section: Questionnairementioning

confidence: 99%

“…Since MOGCTs most often affect young women, there is increasing awareness of long‐term adverse health outcomes following CBCT, including cardiovascular disease, secondary cancer, neuropathy, Raynaud's phenomenon, hearing loss and endocrine abnormalities . Based on a long‐term clinical survey, our group previously reported on some of these adverse health outcomes in MOGCT survivors, but we have yet to deal with the prevalence of peripheral neuropathy and Raynaud phenomenon …”

Section: Introductionmentioning

confidence: 99%

“…6,7 Based on a long-term clinical survey, our group previously reported on some of these adverse health outcomes in MOGCT survivors, but we have yet to deal with the prevalence of peripheral neuropathy and Raynaud phenomenon. 5,[8][9][10] Peripheral neuropathy may occur during CBCT and is one of the most common adverse health outcomes after such treatment. [11][12][13][14][15] Further studies, mostly performed in survivors of testicular cancer, have suggested that peripheral neuropathy usually progresses in the first 3-6 months after CBCT, and subsides thereafter in most patients, although recovery is often incomplete.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Long‐term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin‐based chemotherapy for malignant ovarian germ cell tumor

Solheim

Skalleberg

Warncke

et al. 2018

Acta Obstet Gynecol Scand

Self Cite

View full text Add to dashboard Cite

Introduction The aim was to evaluate “overall neuropathy”, defined as peripheral paresthesia and Raynaud's phenomenon, in long‐term survivors of malignant ovarian germ cell tumors (MOGCTs) treated with cisplatin‐based chemotherapy (CBCT). Material and methods Ninety‐three MOGCT survivors recorded in Norway in 1980‐2009 (median follow up: 15 years) were included in this analysis. Forty‐nine received CBCT (CBCT group) and 44 received other or no chemotherapy (non‐CBCT group). Applying the scale for chemotherapy‐induced neurotoxicity, the prevalence of overall neuropathy (ie score >1 on a 0‐3 scale) was compared between the two groups. Forty women from the CBCT group also underwent neurophysiological and neurological examinations; results from the neurological examination were graded according to the National Cancer Institute‐Common Terminology Criteria for Adverse Effects version 4 (NCI‐CTCAE scale v4). These women were then categorized into subgroups of low (≤3 cycles of CBCT, n = 23) and high CBCT (≥4 cycles of CBCT, n = 17). Results Twenty‐eight (57%) women from the CBCT group reported overall neuropathy, compared with 20 (45%) in the non‐CBCT group (P = .06). Of the 40 MOGCT survivors in the CBCT group who underwent neurophysiological and neurological examinations, 14 (35%) showed NCI‐CTCAE grade ≥1 signs or symptoms of peripheral neuropathy. Pathological findings of NCI‐CTCAE grade 2 or 3 signs or symptoms were found in four survivors (10%) from the high CBCT subgroup, all of whom also showed objective signs of neuropathy. Conclusions Though about half of our MOGCT survivors reported overall neuropathy after CBCT, more severe pathological neurological/neurophysiological findings that impacted daily living were recorded in only 10% of them. Our observations of a similar prevalence of self‐reported overall neuropathy in the CBCT and non‐CBCT group, combined with limited objective neurological findings, warrant further study to increase the understanding of the specific pathophysiological pathways of long‐term CBCT‐induced neuropathy.

show abstract

Section: Questionnairementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Long‐term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin‐based chemotherapy for malignant ovarian germ cell tumor

Solheim

Skalleberg

Warncke

et al. 2018

Acta Obstet Gynecol Scand

Self Cite

View full text Add to dashboard Cite

show abstract

“…Additionally, the few studies exploring quality of life affected by tinnitus do not go into depth into what aspects of life ototoxicity effects [6,41]. Therefore, by exploring these messages from the forums, the exact aspects in ototoxicity affects quality of life can be identified.…”

Section: "I'm Three Years Post Chemo and Now Have Tinnitus In My Leftmentioning

confidence: 99%

“…cisplatin, whilst a highly effective antineoplastic agent, is known to cause peripheral neuropathy and ototoxicity (resulting in tinnitus and hearing loss) [5]. Tinnitus is defined as the manifestation of a conscious perception of an auditory sensation without a corresponding external stimulus [6,7]. These effects can potentially have a significant impact on quality of life.…”

Section: Introductionmentioning

confidence: 99%

Exploring the Experiences of Cancer Patients With Chemotherapy-Induced Ototoxicity: Qualitative Study Using Online Health Care Forums (Preprint)

Pearson¹,

Taylor²,

Hoare³

et al. 2018

Preprint

View full text Add to dashboard Cite

Background: Many cancer patients and survivors experience permanent and life-debilitating effects, such as ototoxicity, from treatment. Ototoxicity manifests as high frequency hearing loss and tinnitus which can have a detrimental effect on the quality of life of those affected. Currently, there is little information and support offered to these patients who experience ototoxicity, potentially leading to many being undiagnosed and untreated.

show abstract

Comprehensive Audiologic Analyses After Cisplatin-Based Chemotherapy

Sanchez,

Dinh,

Monahan

et al. 2024

JAMA Oncol

View full text Add to dashboard Cite

ImportanceCisplatin is highly ototoxic but widely used. Evidence is lacking regarding cisplatin-related hearing loss (CRHL) in adult-onset cancer survivors with comprehensive audiologic assessments (eg, Words-in-Noise [WIN] tests, full-spectrum audiometry, and additional otologic measures), as well as the progression of CRHL considering comorbidities, modifiable factors associated with risk, and cumulative cisplatin dose.ObjectiveTo assess CRHL with comprehensive audiologic assessments, including the WIN, evaluate the longitudinal progression of CRHL, and identify factors associated with risk.Design, Setting, and ParticipantsThe Platinum Study is a longitudinal study of cisplatin-treated testicular cancer survivors (TCS) enrolled from 2012 to 2018 with follow-up ongoing. Longitudinal comprehensive audiologic assessments at Indiana University and Memorial Sloan Kettering Cancer Center included 100 participants without audiometrically defined profound hearing loss (HL) at baseline and at least 3.5 years from their first audiologic assessment. Data were analyzed from December 2013 to December 2022.ExposuresFactors associated with risk included cumulative cisplatin dose, hypertension, hypercholesterolemia, diabetes, tobacco use, physical inactivity, body mass index, family history of HL, cognitive dysfunction, psychosocial symptoms, and tinnitus.Main Outcomes and MeasuresMain outcomes were audiometrically measured HL defined as combined-ears high-frequency pure-tone average (4-12 kHz) and speech-recognition in noise performance measured with WIN. Multivariable analyses evaluated factors associated with risk for WIN scores and progression of audiometrically defined HL.ResultsMedian (range) age of 100 participants at evaluation was 48 (25-67) years; median (range) time since chemotherapy: 14 (4-31) years. At follow-up, 78 (78%) TCS had audiometrically defined HL; those self-reporting HL had 2-fold worse hearing than TCS without self-reported HL (48 vs 24 dB HL; P &lt; .001). A total of 54 (54%) patients with self-reported HL showed clinically significant functional impairment on WIN testing. Poorer WIN performance was associated with hypercholesterolemia (β = 0.88; 95% CI, 0.08 to 1.69; P = .03), lower-education (F1 = 5.95; P = .004), and severity of audiometrically defined HL (β̂ = 0.07; 95% CI, 0.06 to 0.09; P &lt; .001). CRHL progression was associated with hypercholesterolemia (β̂ = −4.38; 95% CI, −7.42 to −1.34; P = .01) and increasing age (β̂ = 0.33; 95% CI, 0.15 to 0.50; P &lt; .001). Importantly, relative to age-matched male normative data, audiometrically defined CRHL progression significantly interacted with cumulative cisplatin dose (F1 = 5.98; P = .02); patients given 300 mg/m2 or less experienced significantly less progression, whereas greater temporal progression followed doses greater than 300 mg/m2.Conclusions and RelevanceFollow-up of cisplatin-treated cancer survivors should include strict hypercholesterolemia control and regular audiological assessments. Risk stratification through validated instruments should include querying hearing concerns. CRHL progression relative to age-matched norms is likely associated with cumulative cisplatin dose; investigation over longer follow-up is warranted.

show abstract

Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer

Cited by 33 publications

References 57 publications

Long‐term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin‐based chemotherapy for malignant ovarian germ cell tumor

Long‐term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin‐based chemotherapy for malignant ovarian germ cell tumor

Exploring the Experiences of Cancer Patients With Chemotherapy-Induced Ototoxicity: Qualitative Study Using Online Health Care Forums (Preprint)

Comprehensive Audiologic Analyses After Cisplatin-Based Chemotherapy

Contact Info

Product

Resources

About